home / stock / inno:cc / inno:cc quote
Last: | $0.57 |
---|---|
Change Percent: | -3.39% |
Open: | $0.55 |
Close: | $0.57 |
High: | $0.57 |
Low: | $0.54 |
Volume: | 40,595 |
Last Trade Date Time: | 05/06/2022 04:57:08 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.57 | $0.55 | $0.57 | $0.57 | $0.54 | 40,595 | 05-06-2022 |
$0.59 | $0.59 | $0.59 | $0.59 | $0.59 | 500 | 05-05-2022 |
$0.6 | $0.56 | $0.6 | $0.6 | $0.54 | 160,791 | 05-04-2022 |
$0.58 | $0.57 | $0.58 | $0.58 | $0.56 | 36,500 | 04-29-2022 |
$0.57 | $0.57 | $0.57 | $0.57 | $0.57 | 700 | 04-28-2022 |
$0.54 | $0.58 | $0.54 | $0.58 | $0.51 | 247,098 | 04-27-2022 |
$0.61 | $0.59 | $0.61 | $0.61 | $0.58 | 197,415 | 04-25-2022 |
$0.61 | $0.61 | $0.61 | $0.62 | $0.61 | 39,503 | 04-22-2022 |
$0.57 | $0.62 | $0.57 | $0.65 | $0.57 | 121,609 | 04-20-2022 |
$0.62 | $0.64 | $0.62 | $0.64 | $0.62 | 24,079 | 04-19-2022 |
$0.64 | $0.61 | $0.64 | $0.64 | $0.61 | 142,501 | 04-18-2022 |
$0.6 | $0.59 | $0.6 | $0.6 | $0.59 | 78,235 | 04-12-2022 |
$0.58 | $0.59 | $0.58 | $0.59 | $0.58 | 25,351 | 04-08-2022 |
$0.6 | $0.6 | $0.6 | $0.6 | $0.6 | 21,900 | 04-07-2022 |
$0.62 | $0.6 | $0.62 | $0.62 | $0.6 | 87,706 | 04-06-2022 |
$0.6 | $0.62 | $0.6 | $0.62 | $0.6 | 74,778 | 04-05-2022 |
$0.6 | $0.6 | $0.6 | $0.6 | $0.6 | 15,001 | 04-04-2022 |
$0.62 | $0.64 | $0.62 | $0.65 | $0.58 | 248,912 | 03-31-2022 |
$0.65 | $0.66 | $0.65 | $0.66 | $0.65 | 75,020 | 03-30-2022 |
$0.68 | $0.62 | $0.68 | $0.68 | $0.61 | 434,389 | 03-29-2022 |
News, Short Squeeze, Breakout and More Instantly...
Innocan Pharma Corporation - Common Shares Company Name:
INNO:CC Stock Symbol:
CNQC Market:
Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million Canada NewsWire HERZLIYA, Israel and CALGARY, AB , May 27, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan...
FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain Canada NewsWire The regulatory approval process with the U.S. Food and Drug Administration has commenced for Innocan's LPT-CBD release technology, marking a key step in the advancement of non-opioid pai...
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey Canada NewsWire HERZLIYA, Israel and ALGARY, AB , May 9, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INN...